Hepatitis C virus infection:are there still specific problems with genotype 3?

作     者：Claire Gondeau Georges Philippe Pageaux Dominique Larrey 

作者机构：Department of Hepato-gastroenterology A Hospital Saint Eloi INSERM U1183Institute of Regenerative Medicine and Biotherapy University of Montpellier 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2015年第21卷第42期

页      面：12101-12113页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：Supported by Agence Nationale de la Recherche sur le SIDA et les Hépatites Virales 

主　　题：Hepatitis C Genotype 3 Direct-acting antivirals In 

摘      要：Hepatitis C virus(HCV) infection is one of the most common causes of chronic liver disease and the main indication for liver transplantation worldwide. As promising specific treatments have been introduced for genotype 1, clinicians and researchers are now focusing on patients infected by non-genotype 1 HCV, particularly genotype 3. Indeed, in the golden era of direct-acting antiviral drugs, genotype 3 infections are no longer considered as easy to treat and are associated with higher risk of developing severe liver injuries, such as cirrhosis and hepatocellular carcinoma. Moreover, HCV genotype 3 accounts for 40% of all HCV infections in Asia and is the most frequent genotype among HCV-positive injecting drug users in several countries. Here, we review recent data on HCV genotype 3 infection/treatment, including clinical aspects and the underlying genotype-specific molecular mechanisms.